Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and in Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Next Previous
Trial Profile

A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and in Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avutometinib (Primary) ; Defactinib (Primary)
  • Indications Adenocarcinoma; Ovarian cancer; Peritoneal cancer
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Acronyms RAMP 201
  • Sponsors Verastem Oncology

Most Recent Events

  • 10 Apr 2026 Results published in the Media Release
  • 10 Apr 2026 According to a Verastem Oncology media release, data from this study will be presented today during an oral plenary session at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting on Women's Cancers taking place in San Juan, Puerto Rico, April 10-13, 2026.
  • 17 Mar 2026 According to a Verastem Oncology media release, company announced it will present new long-term data from the Phase 2 RAMP 201 clinical trial at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting on Women's Cancers. will also be shared at the meeting being held on April 10-13, 2026, in San Juan, Puerto Rico.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top